Lung Transplant Service, Department of Respiratory Medicine, Alfred Hospital and Monash University, Melbourne, Victoria, Australia.
Respirology. 2024 Jun;29(6):458-470. doi: 10.1111/resp.14721. Epub 2024 Apr 22.
Lung transplantation is a well-established treatment for advanced lung disease, improving survival and quality of life. Over the last 60 years all aspects of lung transplantation have evolved significantly and exponential growth in transplant volume. This has been particularly evident over the last decade with a substantial increase in lung transplant numbers as a result of innovations in donor utilization procurement, including the use donation after circulatory death and ex-vivo lung perfusion organs. Donor lungs have proved to be surprisingly robust, and therefore the donor pool is actually larger than previously thought. Parallel to this, lung transplant outcomes have continued to improve with improved acute management as well as microbiological and immunological insights and innovations. The management of lung transplant recipients continues to be complex and heavily dependent on a tertiary care multidisciplinary paradigm. Whilst long term outcomes continue to be limited by chronic lung allograft dysfunction improvements in diagnostics, mechanistic understanding and evolutions in treatment paradigms have all contributed to a median survival that in some centres approaches 10 years. As ongoing studies build on developing novel approaches to diagnosis and treatment of transplant complications and improvements in donor utilization more individuals will have the opportunity to benefit from lung transplantation. As has always been the case, early referral for transplant consideration is important to achieve best results.
肺移植是治疗晚期肺部疾病的成熟方法,可以提高患者的生存率和生活质量。在过去的 60 年中,肺移植的各个方面都取得了显著的进展,移植量呈指数级增长。在过去的十年中,这种情况尤其明显,由于在供体获取方面的创新,包括使用循环死亡后捐献和体外肺灌注器官,肺移植数量大幅增加。供体肺的表现非常出色,因此供体池实际上比以前想象的要大。与此并行的是,随着急性管理、微生物学和免疫学方面的深入理解以及创新技术的应用,肺移植的效果不断得到改善。肺移植受者的管理仍然非常复杂,严重依赖于三级护理多学科模式。虽然长期结果仍然受到慢性肺移植物功能障碍的限制,但在诊断、机制理解和治疗模式方面的改进都有助于使一些中心的中位生存期接近 10 年。随着正在进行的研究在移植并发症的诊断和治疗方面的新方法的基础上不断发展,并改进供体的利用,更多的人将有机会从肺移植中受益。正如以往一样,早期转介进行移植考虑对于取得最佳效果非常重要。